|
Feb 10
|
S&P 500 Gains and Losses Today: Supermicro Stock Surges Ahead of Business Update
|
|
Feb 10
|
Incyte Reports 2024 Financial Results and Outlines 2025 Projections
|
|
Feb 10
|
Why Incyte (INCY) Shares Are Plunging Today
|
|
Feb 10
|
Incyte Stock Sinks as Sales Forecast for Key Drugs Falls Short
|
|
Feb 10
|
INCY's Q4 Earnings Miss Mark, Revenues Beat on Higher Product Sales
|
|
Feb 10
|
Incyte Q4 Earnings: EPS Miss, Strong Jakafi And Opzelura Sales, Says 2025 To Be Catalyst Rich Including 4 Launches
|
|
Feb 10
|
Incyte (INCY) Reports Q4 Earnings: What Key Metrics Have to Say
|
|
Feb 10
|
Incyte forecasts downbeat annual sales of skin disease drug, shares fall
|
|
Feb 10
|
Incyte (INCY) Q4 Earnings Miss Estimates
|
|
Feb 10
|
Incyte (NASDAQ:INCY) Posts Better-Than-Expected Sales In Q4
|
|
Feb 10
|
Incyte: Q4 Earnings Snapshot
|
|
Feb 10
|
Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D Milestones
|
|
Sep 30
|
High Growth Tech Stocks To Watch For Future Potential
|
|
Sep 25
|
Incyte Gains 12.7% Year to Date: How Should You Play the Stock?
|
|
Sep 25
|
Multiple Late-Breaking Data Presentations from Incyte’s Dermatology Portfolio will be Featured at the European Academy of Dermatology and Venereology (EADV) 2024 Congress
|
|
Sep 6
|
Allogene Therapeutics (ALLO) Up 6.4% Since Last Earnings Report: Can It Continue?
|
|
Aug 30
|
Why Is Glaxo (GSK) Up 10.3% Since Last Earnings Report?
|
|
Aug 29
|
Incyte (INCY) Up 0.9% Since Last Earnings Report: Can It Continue?
|
|
Aug 27
|
Exploring Three High Growth Tech Stocks In The United States
|
|
Aug 21
|
Incyte to Present Late-Breaking Phase 3 Results for Retifanlimab (Zynyz®) and Initial Data from Phase 1 CDK2 Inhibitor Program at the European Society of Medical Oncology (ESMO) Congress 2024
|